Threonine
OTHER NAME(S): L-thréonine, L-threonine, Treonina, Thréonine
Overview
Threonine is an essential amino acid. Amino acids are the building blocks of proteins. It cannot be made by the body and must be consumed in foods.
Threonine is changed in the body to a chemical called glycine. Glycine has effects in the brain that might reduce unwanted muscle contractions called spasticity.
People use threonine for Lou Gehrig's disease (amyotrophic lateral sclerosis or ALS), multiple sclerosis (MS), and many other conditions, but there is no good scientific evidence to support these uses.
Don't confuse threonine with another amino acid called theanine. These are not the same.
Uses
Possibly Ineffective for
- Lou Gehrig's disease (amyotrophic lateral sclerosis or ALS). Taking threonine by mouth does not seem to slow the progression of ALS or reduce symptoms.
There is interest in using threonine for a number of other purposes, but there isn't enough reliable information to say whether it might be helpful.
Side Effects
When taken by mouth: Threonine is commonly consumed in foods. People need about 0.5-1 gram of threonine from their diet daily. This amount is considered safe. Threonine is possibly safe when used in larger amounts as a medicine. Doses of up to 4 grams daily have been used safely for up to 12 months. It seems to be well-tolerated. Side effects might include stomach upset, headache, nausea, and skin rash.
Precautions
When taken by mouth: Threonine is commonly consumed in foods. People need about 0.5-1 gram of threonine from their diet daily. This amount is considered safe. Threonine is possibly safe when used in larger amounts as a medicine. Doses of up to 4 grams daily have been used safely for up to 12 months. It seems to be well-tolerated. Side effects might include stomach upset, headache, nausea, and skin rash.
Pregnancy and breast-feeding: Threonine is commonly consumed in foods. But as medicine, there isn't enough reliable information to know if threonine is safe to use when pregnant or breast-feeding. Stay on the safe side and stick to food amounts.
Amyotrophic lateral sclerosis (Lou Gehrig's disease): There is some concern that threonine might decrease lung function in people with ALS. Talk to your healthcare provider before taking threonine if you have ALS.
Interactions
Moderate Interaction
Be cautious with this combination
- Medications for Alzheimer disease (NMDA antagonists) interacts with ThreonineThreonine might decrease the effects of medications for Alzheimer disease.
Dosing
Threonine has most often been used by adults in doses of 1.5-2.5 grams by mouth three times daily for up to 8 weeks. A dose of up to 4 grams daily has been used for up to 12 months. Speak with a healthcare provider to find out what dose might be best for a specific condition.
References
- Monographs on the medicinal uses of plant drugs. Exeter, UK: European Scientific Co-op Phytother, 1997.
- Blumenthal M, ed. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. Trans. S. Klein. Boston, MA: American Botanical Council, 1998.
- Tyler VE. Herbs of Choice. Binghamton, NY: Pharmaceutical Products Press, 1994.
- Newall CA, Anderson LA, Philpson JD. Herbal Medicine: A Guide for Healthcare Professionals. London, UK: The Pharmaceutical Press, 1996.
- Foster S, Tyler VE. Tyler's Honest Herbal: A Sensible Guide to the Use of Herbs and Related Remedies. 3rd ed., Binghamton, NY: Haworth Herbal Press, 1993.
- Tandan R, Bromberg MB, Forshew D, et al. A controlled trial of amino acid therapy in amyotrophic lateral sclerosis: I. Clinical, functional, and maximum isometric torque data. Neurology 1996;47:1220-6.
- Lee A, Patterson V. A double blind study of L-threonine in patients with spinal spasticity. Acta Neurol Scand 1993;88:334-8.
- Blin O, Pouget J, Aubrespy G, et al. A double-blind placebo controlled trial of L-threonine in amyotrophic lateral sclerosis. J Neurol 1992;239:79-81.
- Roufs JB. L-threonine as a symptomatic treatment for amyotrophic lateral sclerosis (ALS). Med Hypotheses 1991;34:20-3.
- Growdon JH, Nader TM, Schoenfeld J, Wortman RJ. L-threonine in the treatment of spasticity. Clin Neuropharmacol 1991;14:403-12.
- Bromberg, M. B., Fries, T. J., Forshew, D. A., and Tandan, R. Electrophysiologic endpoint measures in a multicenter ALS drug trial. J.Neurol.Sci. 2-15-2001;184(1):51-55.
- Testa, D., Caraceni, T., Fetoni, V., and Girotti, F. Chronic treatment with L-threonine in amyotrophic lateral sclerosis: a pilot study. Clin.Neurol.Neurosurg. 1992;94(1):7-9.
- Shakespeare, D. T., Boggild, M., and Young, C. Anti-spasticity agents for multiple sclerosis. Cochrane.Database.Syst.Rev. 2003;(4):CD001332.
- Parton, M., Mitsumoto, H., and Leigh, P. N. Amino acids for amyotrophic lateral sclerosis / motor neuron disease. Cochrane.Database.Syst.Rev. 2003;(4):CD003457.
- Rose, W. C., HAINES, W. J., WARNER, D. T., and JOHNSON, J. E. The amino acid requirements of man. II. The role of threonine and histidine. J.Biol.Chem. 1951;188(1):49-58.
- Hauser, S. L., Doolittle, T. H., Lopez-Bresnahan, M., Shahani, B., Schoenfeld, D., Shih, V. E., Growdon, J., and Lehrich, J. R. An antispasticity effect of threonine in multiple sclerosis. Arch.Neurol. 1992;49(9):923-926.
- Blin, O., Desnuelle, C., Guelton, C., Aubrespy, G., Ardissonne, J. P., Crevat, A., Pouget, J., and Serratrice, G. [Anomaly in the neurotransmitter amino acids in amyotrophic lateral sclerosis: a therapeutic application]. Rev.Neurol.(Paris) 1991;147(5):392-394.
- Parton, M., Mitsumoto, H., and Leigh, P. N. WITHDRAWN: Amino acids for amyotrophic lateral sclerosis / motor neuron disease. Cochrane.Database.Syst.Rev. 2008;(2):CD003457.
- Blin, O., Serratrice, G., Pouget, J., Aubrespy, G., Guelton, C., and Crevat, A. [Short-term double-blind vs placebo trial of L-threonine in amyotrophic lateral sclerosis]. Presse Med. 9-30-1989;18(30):1469-1470.
- Hsieh JTC , Wolfe DL , Connolly S , Townson AF , Curt A , Blackmer J , Sequeira K , and Aubut J. Spasticity after spinal cord injury: an evidence-based review of current interventions. Topics in Spinal Cord Injury Rehabilitation (TOP SPINAL CORD INJ REHABIL) 2007;13(1):81-97.
- National Research Council (US) Subcommittee on the Tenth Edition of the Recommended Dietary Allowances. Recommended Dietary Allowances: 10th Edition. Washington (DC): National Academies Press (US); 1989. 6, Protein and Amino Acids. https://www.ncbi.nlm.nih.gov/books/NBK234922/. Accessed August 7th, 2017.
- Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, DC: The National Academies Press, 2005. Available at: https://doi.org/10.17226/10490